News Stories

The outcomes of a Global think tank on the clinical considerations & management of lipoprotein(a): The top questions and answers regarding what clinicians need to know published online in Progress in Cardiovascular Disease. Participating organizations include the Association of Black Cardiologists, American College of Cardiology, American Heart Association, European Atherosclerosis Society, International Atherosclerosis Society, National Lipid Association, and Preventive Cardiovascular Nurses Association.

Novartis announced that the U.S. Food and Drug Administration (FDA) approved Leqvio (inclisiran) as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with clinical atherosclerotic cardiovascular disease (ASCVD) or heterozygous familial hypercholesterolemia (HeFH) who require additional lowering of LDL-Cholesterol. Inclisiran is the first FDA-approved small interfering RNA (siRNA) therapy to lower low-density lipoprotein cholesterol.

The National Lipid Association would like to extend its congratulations to all of our Fellows of the NLA, current and past, honored at the 2023 National Lipid Association Honors & Awards Ceremony earlier this month: